









市場行情
/
股票
/
nasdaq-crsp
/

CRISPR Therapeutics AG

CRSP

56.250USD

-0.430-0.76%

收盤 12/15, 16:00（美東）報價延遲15分鐘

5.28B總市值

虧損本益比TTM



CRISPR Therapeutics AG

56.250

-0.430-0.76%

概覽公司財務分析

概覽

公司

財務

分析

關於 CRISPR Therapeutics AG 公司

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

CRISPR Therapeutics AG簡介



公司代碼CRSP

公司名稱CRISPR Therapeutics AG

上市日期Oct 19, 2016

CEOKulkarni (Samarth)

員工數量393

證券類型Ordinary Share

年結日Oct 19

公司地址Baarerstrasse 14

城市ZUG

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Switzerland

郵編CH-6300

電話41415613279

網址https://crisprtx.com/

公司代碼CRSP

上市日期Oct 19, 2016

CEOKulkarni (Samarth)

CRISPR Therapeutics AG公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Samarth Kulkarni, Ph.D.

Chairman of the Board, Chief Executive Officer

339.82K

+18.56%

Dr. Raju Prasad, Ph.D.

Chief Financial Officer

13.01K

+30.05%

Mr. John Thomas Greene

Independent Director

7.00K

Dr. Ali Behbahani, M.D.

Independent Director

270.00

Dr. Briggs W. Morrison, M.D.

Director

Mr. James R. Kasinger, J.D.

General Counsel, Secretary

Dr. Naimish Patel, M.D.

Chief Medical Officer

Mr. Sandesh Mahatme

Independent Director

Dr. Katherine A. High, M.D.

Independent Director

Dr. Maria Fardis, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Samarth Kulkarni, Ph.D.

Chairman of the Board, Chief Executive Officer

339.82K

+18.56%

Dr. Raju Prasad, Ph.D.

Chief Financial Officer

13.01K

+30.05%

Mr. John Thomas Greene

Independent Director

7.00K

Dr. Ali Behbahani, M.D.

Independent Director

270.00

Dr. Briggs W. Morrison, M.D.

Director

Mr. James R. Kasinger, J.D.

General Counsel, Secretary

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

ARK Investment Management LLC

10.27%

BlackRock Institutional Trust Company, N.A.

6.56%

Capital International Investors

5.93%

Orbis Investment Management Ltd.

5.23%

State Street Investment Management (US)

4.20%

其他

67.81%

持股股東

佔比

ARK Investment Management LLC

10.27%

BlackRock Institutional Trust Company, N.A.

6.56%

Capital International Investors

5.93%

Orbis Investment Management Ltd.

5.23%

State Street Investment Management (US)

4.20%

其他

67.81%

股東類型

持股股東

佔比

Investment Advisor

43.79%

Investment Advisor/Hedge Fund

23.62%

Venture Capital

3.41%

Research Firm

3.14%

Hedge Fund

2.56%

Individual Investor

1.61%

Bank and Trust

0.52%

Pension Fund

0.44%

Sovereign Wealth Fund

0.43%

其他

20.49%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

980

79.52M

84.90%

+75.16K

2025Q3

1019

79.46M

89.59%

+5.57M

2025Q2

986

73.90M

82.20%

+7.69M

2025Q1

943

66.36M

83.61%

-5.70M

2024Q4

951

66.15M

80.53%

+2.60M

2024Q3

955

62.43M

76.50%

+840.55K

2024Q2

969

61.63M

76.06%

+573.40K

2024Q1

979

61.11M

68.18%

+3.34M

2023Q4

980

54.61M

75.07%

+613.05K

2023Q3

983

54.08M

76.54%

+343.99K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

ARK Investment Management LLC

10.18M

11.2%

+17.19K

+0.17%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.42M

5.96%

+3.00M

+124.40%

Jun 30, 2025

Capital International Investors

5.59M

6.15%

-479.37K

-7.89%

Jun 30, 2025

Orbis Investment Management Ltd.

2.76M

3.04%

+1.20M

+76.88%

Jun 30, 2025

State Street Investment Management (US)

3.27M

3.6%

+859.33K

+35.64%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

3.68M

4.05%

-115.08K

-3.03%

Jun 30, 2025

The Vanguard Group, Inc.

2.28M

2.51%

+528.38K

+30.18%

Jun 30, 2025

UBS Financial Services, Inc.

2.59M

2.85%

+859.43K

+49.73%

Jun 30, 2025

Amova Asset Management Co., Ltd.

2.41M

2.66%

-125.05K

-4.92%

Jun 30, 2025

Amova Asset Management Americas, Inc

2.41M

2.65%

-125.62K

-4.95%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ARK Genomic Revolution ETF

10.33%

Global X Genomics & Biotechnology ETF

5.71%

ARK Innovation ETF

5.12%

AXS Green Alpha ETF

4.84%

WisdomTree BioRevolution Fund

2.81%

Virtus LifeSci Biotech Products ETF

2.48%

State Street SPDR S&P Biotech ETF

2.41%

Direxion Daily S&P Biotech Bull 3X Shares

1.48%

Franklin Genomic Advancements ETF

0.92%

ProShares Ultra Nasdaq Biotechnology

0.59%

ARK Genomic Revolution ETF

佔比10.33%

Global X Genomics & Biotechnology ETF

佔比5.71%

ARK Innovation ETF

佔比5.12%

AXS Green Alpha ETF

佔比4.84%

WisdomTree BioRevolution Fund

佔比2.81%

Virtus LifeSci Biotech Products ETF

佔比2.48%

State Street SPDR S&P Biotech ETF

佔比2.41%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.48%

Franklin Genomic Advancements ETF

佔比0.92%

ProShares Ultra Nasdaq Biotechnology

佔比0.59%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

CRISPR Therapeutics AG的前五大股東是誰？



CRISPR Therapeutics AG的前五大股東如下：
ARK Investment Management LLC
持有股份：10.18M
佔總股份比例：11.20%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.42M
佔總股份比例：5.96%。
Capital International Investors
持有股份：5.59M
佔總股份比例：6.15%。
Orbis Investment Management Ltd.
持有股份：2.76M
佔總股份比例：3.04%。
State Street Investment Management (US)
持有股份：3.27M
佔總股份比例：3.60%。